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Introduction
Multifactorial diseases such as type 2 diabetes,
osteoporosis, and cardiovascular disease are
caused by a complex interplay of many genetic
and nongenetic factors, each of which conveys a
minor increase in the risk of disease.Although the
genetic origin of these diseases is still poorly
understood, enormous progress in the
identification of susceptibility genes is expected
from the large-scale genome-wide associations
[1,2] and biobank initiatives that have been
launched worldwide to investigate the role of
genetic factors in common multifactorial
diseases.[3] The vast amount of information that
will come from these studies will fuel the search
for useful applications of genetic testing for the
prevention and early detection of common
diseases with great public health impact. One of
the greatest promises is that the unraveling of the
genetic origins of common diseases will lead to
individualized medicine, in which prevention and
treatment strategies are personalized on the basis
of the results of predictive genetic tests. Examples
of multifactorial diseases showing promise for
predictive genetic testing include type 2 diabetes
and age-related macular degeneration.[4,5]
This great optimism,however,is counterbalanced
by concerns about the ethical, legal, and social
implications of genomic medicine, such as the
protection of privacy and autonomy,stigmatization,
discrimination, and the psychological burden of
genetic testing.[6,7] These concerns about
potential adverse consequences are translated from
genetic testing in monogenic disorders, which is
available for more than 1,000 disorders. [8] Most of
these applications are to confirm diagnoses in rare
syndromes,but others are used for prenatal testing,
newborn screening, and presymptomatic carrier
testing. For example, pregnant women can be
tested for selected congenital anomalies in their
offspring,and relatives of patients with Huntington
disease and hereditary forms of cancer can be
tested for their predisposition to disease long
before the onset of symptoms.
Multifactorial diseases, however, are essentially
different from monogenic diseases, which raises
the question of to what extent the same ethical,
legal, and social issues are relevant. The
participants of the Bellagio initiative clearly
emphasized that the discussion of ethical, legal,
and social issues should acknowledge the
fundamental differences between predictive
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Abstract
Multifactorial diseases such as type 2 diabetes, osteoporosis, and cardiovascular disease are caused by a
complex interplay of many genetic and nongenetic factors, each of which conveys a minor increase in the risk
of disease. Unraveling the genetic origins of these diseases is expected to lead to individualized medicine, in
which the prevention and treatment strategies are personalized on the basis of the results of predictive genetic
tests. This great optimism is counterbalanced by concerns about the ethical, legal, and social implications of
genomic medicine, such as the protection of privacy and autonomy, stigmatization, discrimination, and the
psychological burden of genetic testing. These concerns are translated from genetic testing in monogenic
disorders, but this translation may not be appropriate. Multiple genetic testing (genomic profiling) has
essential differences from genetic testing in monogenic disorders. The differences lie in the lower predictive
value of the test results, the pleiotropic effects of susceptibility genes, and the low inheritance of genomic
profiles. For these reasons, genomic profiling may be more similar to nongenetic tests than to predictive tests
for monogenic diseases. Therefore, ethical, legal, and social issues that apply to predictive genetic testing for
monogenic diseases may not be relevant for the prediction of multifactorial disorders in genomic medicine. 
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genetic testing for monogenic diseases and that
for multifactorial diseases:“the widespread use of
Huntington’s disease as a paradigm for genetics in
medicine should be actively discouraged as it
gives a very misleading idea of the predictive
power of genetic information for most people.”[9]
Essential differences between genetic testing for
monogenic diseases and that for multifactorial
diseases include the predictive value of the test
results, the pleiotropic effects of susceptibility
genes, and the inheritance of genomic profiles. In
this article, we elucidate and illustrate these three
differences and discuss how they may influence
the discussion about ethical, legal, and social
issues in genomic medicine.
Predictive value of genetic testing
Monogenic diseases
Monogenic diseases such as Huntington disease,
familial hypercholesterolaemia, cystic fibrosis, and
several hereditary forms of cancer are completely
or predominantly caused by mutations in a single
gene. Predictive testing for these causal genes is
very informative because disease risks differ
substantially between carriers and noncarriers of
the mutations. Shown in Figure 1 are the
differences in disease risk between carriers and
noncarriers of the risk variants for Huntington
disease, hereditary breast cancer, and
nonpolyposis colorectal cancer.[10-12] These
mutations are typically rare, and therefore carriers
have a substantial increased risk of disease, and
noncarriers have a disease risk that approximates
the population average.
Because of the large differences in disease risk
between carriers and noncarriers, genetic testing
can be useful for targeting preventive or
therapeutic interventions to the relatively small
group of individuals at increased risk of disease.
Examples include intensive surveillance and
prophylactic surgery for breast and ovarian cancer
and prescription of statins for familial
hypercholesterolemia. Genetic testing is also
considered valuable in the absence of effective
interventions to relieve uncertainty—also in the
case of positive test results—and to prepare for the
future. But the high predictive value of genetic
testing can also be used for undesired purposes—
from the perspective of the individual who tests
positive—for example, by insurers to determine
the conditions and premiums of insurance. It is for
this reason that ethical, legal, and social issues are
an integral part of the evaluation of genetic testing.
Multifactorial diseases
Because multifactorial diseases are caused by a
complex interplay of many genetic and non-
genetic factors, the predictive value of testing for
a single genetic variant is limited.The disease risk
in carriers of the risk variant is only slightly higher
than that in non-carriers. For example, several
examples of genetic test results for predicting
type 2 diabetes are shown in Figure 2. Because
risk variants are generally common (>1%),carriers
and noncarriers have disease risks that are only
slightly higher or lower, respectively, than the
population average.The differences in disease risk
are less profound, and noncarriers retain a
substantial risk of disease.
An exception is the TCF7L2 gene for which
homozygous carriers of the risk variant have a risk
of type 2 diabetes of 63% compared with 26% in
noncarriers. This does not necessarily imply that
that TCF7L2 carrier testing is useful in a
prevention program for type 2 diabetes, however.
Although homozygous carriers (7% of the
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Figure 1. Disease risks of carriers and noncarriers in genetic testing for monogenic disorders
Legend: The genetic variants tested are CAG repeats in 4p16.3 for Huntington disease,10 BRCA1/BRCA2 for breast cancer,11 and
hMLH1/hMSH2 for colorectal cancer.12
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population) may be more motivated to adopt a
healthier lifestyle to lower their diabetes risk, in
practice behavioral changes are difficult to
achieve.[13] Moreover, even if a 100% effective
treatment were available to eliminate the negative
effects of the risk alleles, 63% of the homozygous
and 88% of the heterozygous carriers would not
benefit from the intervention because they either
would not develop diabetes despite their TCF7L2
carrier status or would develop diabetes for other
reasons.[14]
Because multiple genetic and nongenetic
factors each have only a minor role in the etiology
of multifactorial diseases, genetic prediction of
disease will be based on testing for multiple
genetic variants simultaneously. This is called
genomic profiling. A genomic profile describes
the genotype status for all tested variants.Suppose
we test five genetic variants to predict disease,
which each come in two genotypes: a risk
genotype (R) that increases the risk and a normal
genotype (N) that decreases the risk of disease.
The possible results of this combined test include
N-N-R-R-N and R-N-N-N-R, which represent two
among the 32 that are possible based on five
variants with two genotypes. These profiles may
reflect different underlying pathways for
developing the disease that may not necessarily
be prevented or treated with the same
interventions. Yet, when the aim is prediction of
disease rather than positive response to specific
interventions, then these underlying pathways
can be considered secondary.That is, what counts
is the genotype status of the genes tested and the
degree to which they increase or decrease the risk
of disease.
The risk of disease associated with a genomic
profile is a function of the person’s genotype
status for all genetic variants that increase or
decrease the disease risk. When single genetic
variants are equally associated with increased risk
of disease, e.g., when all risk variants increase the
risk of disease by 50%, it does not matter for the
prediction of disease on which gene a risk variant
is carried. In the aforementioned example, both
profiles have two risk and three normal genotypes
out of five variants tested. Prediction of disease
can then simply be based on the number of risk
genotypes in the genomic profiles: the more risk
genotypes, the higher the risk of disease. This is
also illustrated in Figure 3, which simulates a
population of 1 million persons for whom
genotype and disease status are known and in
which the average disease risk is 10%. The data
were simulated using a procedure that has been
described previously in more detail.[15] The
hypothetical frequencies of risk genotypes for 40
genes vary from 1% to 60%. Figure 3a gives the
expected distribution of the number or risk
genotypes when the 40 genes are tested
simultaneously. The figure shows that all
individuals have at least some risk genotypes and
none have risk genotypes for all genes tested.
Figure 3b shows the associated risk when each
single risk genotype increases the risk of disease
by 50% (odds ratio = 1.5).The figure shows that
the more risk genotypes that are present, the
higher the risk of disease. Multiple genetic testing
could identify genomic profiles associated with
very high disease risks, but these are rare. Most of
the individuals have disease risks that are only
slightly higher or lower than the average disease
risk in the population.
Finally, in Figure 3c we consider a more realistic
scenario in which some genetic factors are
stronger predictors of disease than others. The
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Figure 2. Disease risks of carriers and noncarriers in single genetic testing for multifactorial disorders 
Legend: Data on the odds ratios of the genetic variants are obtained from the literature (PPARG[30], CAPN10[31], TCF7L2[32]). For the
calculation of the disease risks from the published odds ratios, we assumed a lifetime risk of type 2 diabetes of 33%.[33]
odds ratios of the individual genetic variants vary
from 1.05 for the frequent risk genotypes to 2.0
for the rare risk genotypes. In this case, the disease
risks not only increase with the number of risk
genotypes in the profiles, but also within each
category defined by the number of risk
genotypes. The result is a scatter of disease risks
rather than clearly distinguishable risk categories.
This scenario, in which both the frequency and
the effect size of the risk genotype vary, is the
most likely scenario to be expected for the
distribution of disease risks associated with
genomic profiles. Note, however, that these
examples do not consider the role of
environmental factors. These factors would
contribute to further variation in disease risks for
individuals with the same genomic profile.
Pleiotropic effects of susceptibility genes
In the next decades, genome-wide association
studies and biobank initiatives will help to identify
the numerous weak susceptibility genes involved
in multifactorial diseases. These discoveries will
lead to the construction of genomic profiles for the
prediction of common disorders, such as type 2
diabetes, osteoporosis, asthma, Alzheimer disease,
and cancer. Separate profiles will be constructed
for different diseases and will therefore differ in the
genetic variants included. Many susceptibility
genes, however, are associated with increased risk
of more than one disease, and hence can be
included in more than one genomic profile. An
example is the tumor necrosis factor α (TNF-α)
–308G/A polymorphism, for which carriers of the
risk allele have an increased risk of non-hodgkin
lymphoma, obesity, and asthma.[16-18] Such
pleiotropic effects typically occur when diseases
share causal pathogenetic pathways.In the extreme
case, when there is considerable overlap in the
causal pathways between two diseases, for
example, as for hypertension and coronary heart
disease, a genomic profile designed for one disease
can also be predictive of the other, albeit with a
lower predictive value.
Not only can susceptibility genes be involved in
multiple disorders, but they can also increase the
risk of some diseases and decrease the risk of
others. For example, deletions in the angiotensin-
converting enzyme (ACE) gene insertion/deletion
(I/D) polymorphism are associated with a
decreased risk of Alzheimer disease and an
increased risk of stroke,[19,20] and homozygous
carriers of the interleukin-6 (IL-6) -174G/C
polymorphism also have a decreased risk of
Alzheimer disease and an increased risk of intima
media thickness, a risk factor for stroke and
myocardial infarction.[21,22] This could have
important implications for the prevention of
disease, particularly when genomic profiling is
applied for targeting pharmacogenomic
interventions. Preventive and therapeutic
interventions aimed at eliminating the negative
effects of a single genetic variant for one disease
may increase the risk of another disease.
Inheritance of genomic profiles
A third essential difference between genetic
testing for autosomal dominant monogenic
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Figure 3. Disease risks associated with profiles in genetic testing for multifactorial disorders
Legend: Bars indicate the frequency distribution of the genomic profiles quantified by the number of risk genotypes in the profile. The
frequencies are presented on the left axis. The scatter plots represent the disease risks associated with the genomic profiles when all
individual variants have the same odds ratio (OR=1.5; Figure 3b) and when the odds ratios vary (Figure 3c). The disease risks are
presented on the right axis. Genomic profiles were constructed using a previously described method.15 We assumed that the disease
risk in the population was 10% and that the frequencies of the risk genotypes varied between 1 and 60% (incremental from 1 to 19%
by 1% and from 20 to 60% by 2%). In Figure 3c we assumed that the odds ratios varied from 1.05 to 2.0 (incremental from 1.05 to 1.19
by 0.01 and from 1.20 to 2.0 by 0.05).
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disorders and genomic profiling for complex
diseases is the disease implications for relatives.
Results of genetic tests for autosomal dominant
conditions are also informative for close relatives,
particularly parents and children. When one
parent is identified as a heterozygous carrier of an
autosomal dominant gene, children have a 50%
risk of inheriting the risk variant from that parent
and, depending on the penetrance, have a
substantial risk of developing the disease.
When testing multiple genetic variants
simultaneously, however, it is less likely that close
relatives share identical profiles.The probability of
inheriting the same genomic profile depends on
the number of genetic variants that are tested
simultaneously and is low when the number is
large. In fact, when 20 autosomal dominant
susceptibility variants are tested and one parent is
a heterozygous carrier for all variants, then the
probability that a child inherits all risk alleles from
that parent is 0.5020, or approximately 1 in one
million.This probability is higher when the other
parent also contributes risk alleles, which is likely
when risk alleles are common.Generally,however,
inheriting exactly the same profile is unlikely.
Implications for ethical, legal, and social issues
of genetic testing
Ensuring the appropriate evaluation of genetic
testing and genome-based prevention programs is
fundamentally an ethical concern for those
responsible for efforts to promote population
health.[9] This includes the prevention and
monitoring of potential adverse ethical, legal, and
social consequences of genetic testing. Yet, which
issues are relevant in the evaluation of predictive
genetic testing also depends on the nature of the
test.We have described three differences between
genetic testing for monogenic disorders and that for
multifactorial disorders, which not only influence
the clinical and public health utility of genetic
testing,[14,15,23] but also may affect the discussion
of ethical, legal, and social issues, especially
discrimination and stigmatization, privacy, and the
psychological impact of genetic testing.
Discrimination and stigmatization concern the
differential treatment of individuals based, in this
case,on their genetic predisposition for a particular
disease.The most illustrative example is the use of
genetic test results by insurers to determine the
conditions and premiums of insurance. Although
fear of discrimination may lead individuals to
decide against predictive genetic testing,[6] most
insurance applicants are accepted at the standard
conditions.[24] Discrimination and stigmatization
based on genetic predisposition require clearly
distinguishable subgroups between which the
disease risks differ to such an extent that
differentiation of the conditions and premiums
outweighs the costs of obtaining additional
information about genetic predisposition.Knowing
that genomic profiling yields a continuum of
disease risks rather than distinct risk categories,
that most individuals will have risks that are only
slightly higher or lower than the population
average, and that individuals may be at increased
risk of some diseases and at decreased risk of
others makes it less likely that genomic profiling
can be used for purposes other than disease
prediction.Also, genetic discrimination of relatives
of patients with multifactorial diseases may be
unlikely because of the low probability of
inheriting the completely same profile.
The protection of privacy is a key issue in
predictive genetic testing because the results of
genetic tests also inform close relatives about their
carrier status, even when they have no intention
toward genetic testing themselves,and because the
test results can inform asymptomatic individuals
about their disease risks in later life. These issues
are particularly important in monogenic disorders,
for which close relatives have a substantial risk of
carrying the same risk genotype and for which
carrier status has high predictive value.These issues
may be less relevant in predictive testing for
multifactorial diseases by genomic profiling,
because the probability of inheriting the same
genomic profile is very low and disease risks
associated with most genomic profiles are only
moderately higher or lower than the population
average. Moreover, disease risks are codetermined
by environmental factors, which leaves the door
open for personal or medical interventions to
reduce the effect of the risk information.
The adverse psychological consequences of
genetic testing for monogenic diseases such as
hereditary cancers and Huntington disease have
been intensively studied.25;26 These studies indicate
that after a period of distress during and around the
time of the testing procedures,individuals generally
cope well with the adverse results of genetic
testing.[25,26] Nevertheless, researchers warn that
psychological distress is underestimated in
longitudinal studies because of a selective loss to
follow-up.[27,28] A question is whether adverse
psychological consequences should also be
expected in genomic profiling. Most at-risk profiles
are associated with disease risks that are only
moderately higher than the population average.
Moreover, genetic predisposition for multifactorial
disorders is less deterministic in the sense that
these diseases are caused by an interplay of genetic
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and nongenetic factors, and the latter often allow
for risk reduction through changes in lifestyle
factors such as diet, smoking and exercise. These
factors combined suggest that the adverse
consequences of predictive genetic testing for
common diseases may not be that severe.
While ethical, legal and social issues that apply in
monogenic testing may be less relevant for
genomic profiling, new issues may arise. One
concern is whether it is ethical to offer genetic
tests with low predictive value or tests that have
not been thoroughly and systematically examined
for their predictive value. Genomic profiling is
already available through the internet e.g., for
personalized lifestyle and diet recommendations.
Although these tests are presently not validated and
not recommended clinically, people buy these
online tests. Apart from being uninformative and
misleading, such premature use of genetic
information may hamper the trustworthiness and
integrity of future applications.
Concluding remarks
Ethical, legal, and social issues are an integral part
of the evaluation of health care and are not unique
to genomic medicine.[29] Many issues that apply in
predictive genetic testing, such as privacy and
autonomy,have a broader scope because they apply
to all or most medical procedures and programs.
Some other issues are particularly relevant to
predictive testing, irrespective of whether it is
genetic or nongenetic; some are particularly
relevant in genetic testing,irrespective of whether it
is predictive or diagnostic; and others are specific
for predictive genetic testing. In this article, we
made a further distinction and elucidated that
ethical, legal, and social issues that apply to
predictive genetic testing for monogenic diseases
may not be relevant for the prediction of
multifactorial disorders.This distinction is important
to ensure that the progress in genomics research
and the development of genome-based prevention
programs are accompanied by a meaningful debate
of the ethical, legal, and social issues.
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